Daily Cardiology Research Analysis
Analyzed 216 papers and selected 3 impactful papers.
Summary
Three impactful cardiology studies stood out today: a PROSPERO-registered meta-analysis shows that early aspirin discontinuation (≤3 months) with ticagrelor/prasugrel monotherapy after PCI reduces bleeding without increasing myocardial infarction when timed appropriately; a systematic review identifies microvascular resistance reserve (MRR) as an independent prognostic marker with an actionable threshold (~3); and a large All of Us cohort links lower socioeconomic status to higher incident heart failure and worse outcomes.
Research Themes
- Optimizing antiplatelet therapy timing after PCI
- Prognostic microvascular physiology (MRR) in CAD
- Socioeconomic determinants of heart failure incidence and outcomes
Selected Articles
1. Early aspirin withdrawal versus dual antiplatelet therapy in high-risk patients after percutaneous coronary intervention: Meta-analysis of randomized trials.
Across seven RCTs (n=27,743), switching to ticagrelor/prasugrel monotherapy within 3 months reduced bleeding (HR 0.55) without increasing MI overall; however, immediate aspirin noninitiation/cessation raised MI risk, while post-discharge early discontinuation did not. Trial sequential and Bayesian analyses supported conclusiveness for bleeding benefit, with risk-aligned timing recommendations.
Impact: This synthesis resolves timing uncertainty by separating “immediate” vs “early” aspirin discontinuation and quantifies trade-offs using TSA and Bayesian methods, offering practice-changing clarity for post-PCI antiplatelet strategies.
Clinical Implications: Avoid immediate aspirin noninitiation/cessation after PCI; consider discontinuing aspirin within 1–3 months while continuing ticagrelor/prasugrel monotherapy, tailoring timing to bleeding vs ischemic risk (earlier in high bleeding risk, later in high ischemic risk).
Key Findings
- P2Y12-inhibitor monotherapy after ≤3 months reduced clinically relevant bleeding vs continued DAPT (HR 0.55, 95% CI 0.42–0.71).
- No overall increase in MI with early aspirin withdrawal (HR 1.11, 95% CI 0.91–1.35); immediate noninitiation/cessation increased MI (HR 1.41), early post-discharge discontinuation did not (HR 0.97).
- Trial sequential analysis showed conclusiveness for bleeding benefit and futility for excess MI; Bayesian analyses yielded risk-aligned timing recommendations (e.g., ≤1 month in high bleeding risk).
Methodological Strengths
- PROSPERO-registered, comprehensive meta-analysis of randomized trials with PRISMA methods
- Use of Bayesian modeling and trial sequential analysis to assess conclusiveness and risk-aligned timing
Limitations
- Aggregate-level data limit patient-level subgroup analyses
- Precision limited for the immediate aspirin withdrawal subgroup
Future Directions: Prospective, patient-level randomized comparisons of timing strategies stratified by bleeding and ischemic risk; evaluation in broader stent types and real-world polypharmacy.
BACKGROUND: Patients at high ischemic or bleeding risk after percutaneous coronary intervention (PCI) require protection against thrombotic events with dual antiplatelet therapy (DAPT) while avoiding bleeding. Although guidelines recommend 12-month DAPT after acute coronary syndrome (ACS), recent trials have tested the safety of early aspirin withdrawal with potent P2Y12-inhibitor monotherapy. METHODS AND FINDINGS: We performed a meta-analysis of randomized trials (from inception through August 2025) comparing early aspirin withdrawal (≤3 months) with transition to ticagrelor- or prasugrel-monotherapy versus continued DAPT. Co-primary outcomes were myocardial infarction (MI) and clinically relevant bleeding. Prespecified timing analyses stratified the comparison versus DAPT by aspirin timing: immediate (aspirin noninitiation or in-hospital cessation) and early (post-discharge discontinuation within 3 months). Bayesian models quantified risk-stratified probabilities of benefit and harm; trial sequential analysis (TSA) assessed conclusiveness of evidence. Seven trials (n = 27,743) were included. P2Y12-inhibitor monotherapy reduced bleeding (HR = 0.55, 95% CI [0.42, 0.71]; p < 0.001) without significantly increasing MI overall (HR = 1.11, 95% CI [0.91, 1.35]; p = 0.31), death, stroke, or stent thrombosis. Immediate aspirin noninitiation/cessation increased MI (HR = 1.41, 95% CI [1.01, 1.97]; p = 0.04), whereas early discontinuation did not (HR = 0.97, 95% CI [0.76, 1.24]; p = 0.82). TSA indicated conclusiveness for bleeding benefit and futility for an MI excess. Analyses restricted to ACS confirmed the overall results. Bayesian analyses corroborated these effects and identified risk-aligned timing: in high bleeding risk, ≤1-month aspirin discontinuation yielded a 100% posterior probability of bleeding benefit (NNT = 12) and 70% probability of MI-safety; in high ischemic risk, 3-month aspirin discontinuation yielded 100% probability of bleeding benefit (NNT = 57) and 86% probability of MI-safety. Limitations include aggregate data only and limited precision for the immediate aspirin withdrawal subgroup. CONCLUSIONS: Among high-risk post-PCI patients on ticagrelor/prasugrel, discontinuing aspirin within 3 months reduces bleeding without an ischemic trade-off versus DAPT. Immediate aspirin noninitiation or cessation should be avoided; timing should be individualized to bleeding and ischemic risk. PROSPERO: CRD420251167706.
2. Prognostic Value of Microvascular Resistance Reserve in Coronary Artery Disease: A Systematic Review and Meta-Analysis.
Across five prospective studies (n=3,186), each unit increase in MRR was associated with a 25% relative reduction in adverse cardiovascular events, with stronger prognostic impact in acute coronary syndromes. A threshold around 3 optimized prognostic discrimination, supporting MRR’s integration into invasive physiologic assessment.
Impact: Standardizes microvascular prognostication with an actionable threshold, positioning MRR as a candidate for routine invasive physiology beyond epicardial stenosis assessment.
Clinical Implications: Consider measuring MRR during invasive assessment to refine risk stratification, particularly in ACS and in patients with non-obstructive CAD; an MRR ≥3 may indicate preserved microvascular reserve and lower risk.
Key Findings
- Higher MRR associated with lower adverse event risk (pooled HR per unit increase 0.75; 95% CI 0.64–0.88).
- Prognostic impact of MRR was stronger in acute coronary syndrome presentations.
- An MRR threshold around 3 provided the best balance for prognostic discrimination.
Methodological Strengths
- PRISMA-guided systematic review with prospective studies and random-effects pooling
- Risk of bias assessed using Quality in Prognosis Studies (QUIPS) tool
Limitations
- Limited number of studies and potential heterogeneity in MRR measurement protocols
- Prognostic meta-analyses remain observational, susceptible to residual confounding
Future Directions: Standardize MRR acquisition and validation across centers; prospective studies to test MRR-guided management and its incremental value over CFR/IMR and epicardial physiology.
BACKGROUND: Microvascular resistance reserve (MRR) is a novel index for evaluating coronary microvascular function independently of epicardial disease. Its prognostic significance in coronary artery disease (CAD) remains uncertain. OBJECTIVES: The aim of this study was to assess the association between MRR and adverse cardiovascular outcomes across various CAD presentations. METHODS: A systematic review and meta-analysis was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. MEDLINE and Embase were searched from January 2019 to January 2025 for prospective studies reporting HRs for major adverse cardiovascular events in relation to MRR. Risk for bias was assessed using the Quality in Prognosis Studies tool. Pooled HRs were calculated using a random-effects model; heterogeneity was evaluated using the I RESULTS: Five studies (n = 3,186) were included. Higher MRR was significantly associated with lower risk for adverse events (HR per unit increase: 0.75; 95% CI: 0.64-0.88; I CONCLUSIONS: MRR is a robust, independent predictor of cardiovascular outcomes of both acute and chronic CAD. Its prognostic impact is particularly pronounced for acute coronary syndrome. A threshold of 3 provides the best prognostic balance, supporting its integration into invasive physiological assessment for risk stratification.
3. Socioeconomic Correlates of Incident Heart Failure and Consequent Mortality: The All of Us Program.
In 280,431 adults without HF, lower income, lower education, and higher neighborhood deprivation independently increased incident HF risk with graded associations; benefits of higher education were attenuated in non-White and deprived neighborhoods. Among 10,550 with prevalent HF, higher income modestly lowered all-cause mortality.
Impact: Leverages a large, diverse EHR-linked cohort to quantify independent and interacting socioeconomic drivers of incident HF and mortality, informing precision prevention and policy.
Clinical Implications: Incorporate SES (income, education, neighborhood deprivation) into HF risk assessment; prioritize prevention and access strategies in socioeconomically disadvantaged groups and monitor equity-sensitive outcomes.
Key Findings
- Income showed a strong graded association with incident HF (HR up to 3.02 for <$25,000 vs ≥$200,000).
- Lower education and higher Area Deprivation Index independently increased HF risk; education was less protective in non-White participants and deprived neighborhoods.
- Among prevalent HF, each $10,000 increase in income associated with 3% lower all-cause mortality.
Methodological Strengths
- Very large, diverse national cohort with EHR linkage and standardized SES measures
- Robust Cox modeling with interaction analyses across race and neighborhood deprivation
Limitations
- Observational design subject to residual confounding and potential misclassification of SES
- Education and income effects may be influenced by unmeasured access and environmental factors
Future Directions: Test SES-informed risk models and targeted interventions in pragmatic trials; integrate social risk adjustment into HF prevention programs and evaluate equity outcomes.
BACKGROUND: Although socioeconomic status (SES) is a known determinant of cardiovascular disease, the independent risks of incident heart failure (HF) and consequent mortality portended by individual and neighborhood measures of SES remain less established. OBJECTIVES: This study sought to evaluate the prospective associations of SES with HF in adults without HF and SES with all-cause mortality in those with HF. METHODS: The authors identified adults from the National Institutes of Health-run All of Us Research Program (2018-present) who consented to share their electronic health records. Among 280,431 participants free of HF and 10,550 participants with prevalent HF, Cox proportional hazards models assessed associations of income, education, and Area Deprivation Index (ADI) with risks of incident HF and mortality. RESULTS: Over 41 ± 23 months, 6,783 of 280,431 participants developed HF. Compared with household income ≥$200,000, risk was higher for $100,000 to <$200,000 (HR: 1.29; 95% CI: 1.12-1.48), $50,000 to <$100,000 (HR: 1.82; 95% CI: 1.60-2.09), $25,000 to <$50,000 (HR: 2.24; 95% CI: 1.95-2.57), and <$25,000 (HR: 3.02; 95% CI: 2.63-3.47). Relative to college graduates, risk was higher for those with some college (HR: 1.37; 95% CI: 1.28-1.46), General Educational Development (HR: 1.46; 95% CI: 1.36-1.58), and less than high school (HR: 1.40; 95% CI: 1.26-1.55). Compared with the least deprived tertile of ADI, risk was higher in the middle tertile (HR: 1.21; 95% CI: 1.14-1.29) and the most deprived tertile (HR: 1.18; 95% CI: 1.11-1.26). Non-White participants and residents of the most deprived ADI tertiles experienced less benefit from higher education. Among those with prevalent HF, each $10,000 increase in income was associated with 3% lower all-cause mortality. CONCLUSIONS: Lower income, education, and high neighborhood deprivation independently associate with incident HF, whereas only income was associated with mortality. Higher education was less protective in non-White participants and individuals residing in deprived neighborhoods. Addressing these disparities is essential to reducing HF burden and consequent mortality.